Active Investor and Media Outreach to Build Company Awareness as a
Leading Parthenogenetic Stem Cell Company
International Stem Cell Corporation (OTCBB:ISCO), the first company to
perfect a method of creating human stem cells from unfertilized eggs,
has retained the Investor Relations Group (IRG), a highly recognized
corporate communications firm based in New York City, to serve as its
national investor and public relations firm.
International Stem Cell is the first company to perfect a method of
creating human stem cells from unfertilized eggs. These cells, called "parthenogenetic"
stem cells, promise to avoid two critical problems inherent in cell
transplantation today: immune rejection and the ethical issues
associated with the use of fertilized human embryos. ISCO, through its
wholly owned subsidiary, Lifeline Cell Technology, develops and
manufactures cell culture products for research use and currently
generates revenue and therapeutic production capacity for the Company.
The Investor Relations Group's team will use
proprietary competitive analysis strategies and extensive databases to
target the broad scope of the investment community, including portfolio
managers and analysts. IRG's program will
include pre-qualified one-on-one introductions, e-mail campaigns to
investment professionals that have opted-in for communication, and
traditional outreach. Simultaneously, the thirteen-year-old firm's
award-winning public relations department will initiate an outreach
campaign to the media, namely editors, writers, and producers of local
and national trade and consumer print publications, online portals,
radio, and broadcast media outlets. Together the team's
mandate will be to educate and communicate International Stem Cell's
corporate strategy, key initiatives for growth, and ongoing company
developments to both the investment community and general public.
"We are at an inflection point in ISCO's
history and we feel it is the right time for IRG to begin building
awareness and communicating the story of our unique stem cell technology
to the investment community, media-at-large, and general public,"
said Ken Aldrich, Chairman and CEO of International Stem Cell. "As
we move forward with our vision for growth, we look forward to IRG
relaying our corporate objectives to the appropriate target audiences." About The Investor Relations Group, Inc.:
The Investor Relations Group, Inc. (IRG) offers a full-service corporate
communications program designed to suit the many unique needs of public
companies. The program utilizes a proprietary, targeted approach to
reach institutional investors, analysts, and the media-at-large. For
further information, please visit the company's website at www.investorrelationsgroup.com.
About International Stem Cell Corporation:
International Stem Cell Corporation (ISCO) is a California biotechnology
company focused on developing therapeutic and research products. ISCO's
technology, Parthenogenesis, results in the creation of pluripotent
human stem cell lines from unfertilized human eggs. ISCO scientists also
have created the first Parthenogenetic homozygous stem cell line
(phSC-Hhom-4) that can be a source of therapeutic cells that will not be
immune rejected after transplantation into millions of individuals of
differing sexes, ages and racial groups. These advancements offer the
potential to create the first true "Stem Cell
Bank" and address ethical issues by
eliminating the need to use or destroy fertilized embryos. ISCO also
produces and markets specialized cells and growth media worldwide for
therapeutic research through its subsidiary Lifeline Cell Technology.
For more information, visit the ISCO website at: www.internationalstemcell.com.
To subscribe to receive ongoing corporate communications please click on
the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.
Forward-Looking Statements Statements pertaining to future financial and/or operating results,
future growth in research, technology, clinical development and
potential opportunities for the company and its subsidiary, along with
other statements about the future expectations, beliefs, goals, plans,
or prospects expressed by management constitute forward-looking
statements. Any statements that are not historical fact (including, but
not limited to statements that contain words such as "will,""believes,""plans,""anticipates,""expects,""estimates,")
should also be considered to be forward-looking statements.
Forward-looking statements involve risks and uncertainties, including,
without limitation, risks inherent in the development and/or
commercialization of potential products, uncertainty in the results of
clinical trials or regulatory approvals, need and ability to obtain
future capital, and maintenance of intellectual property rights. Actual
results may differ materially from the results anticipated in these
forward-looking statements and as such should be evaluated together with
the many uncertainties that affect the company's business, particularly
those mentioned in the cautionary statements found in the company's
Securities and Exchange Commission filings. The company disclaims any
intent or obligation to update these forward-looking statements.
The Investor Relations Group 212-825-3210 Investor Relations: Adam
Holdsworth aholdsworth@investorrelationsgroup.com or Erica
Ruderman eruderman@investorrelationsgroup.com or Brett
Foley bfoley@investorrelationsgroup.com or Media
Relations: Laura Colontrelle lcolontrelle@investorrelationsgroup.com |